1. Home
  2. ANIX vs GNTA Comparison

ANIX vs GNTA Comparison

Compare ANIX & GNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Anixa Biosciences Inc.

ANIX

Anixa Biosciences Inc.

HOLD

Current Price

$2.78

Market Cap

114.0M

Sector

Health Care

ML Signal

HOLD

Logo Genenta Science S.p.A.

GNTA

Genenta Science S.p.A.

HOLD

Current Price

$0.69

Market Cap

33.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ANIX
GNTA
Founded
1982
2014
Country
United States
Italy
Employees
N/A
9
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
114.0M
33.8M
IPO Year
2013
2021

Fundamental Metrics

Financial Performance
Metric
ANIX
GNTA
Price
$2.78
$0.69
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
★ $8.67
N/A
AVG Volume (30 Days)
★ 352.7K
53.6K
Earning Date
05-27-2026
03-24-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 12.82
N/A
EPS
N/A
★ N/A
Revenue
★ $210,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.32
$0.55
52 Week High
$5.46
$10.00

Technical Indicators

Market Signals
Indicator
ANIX
GNTA
Relative Strength Index (RSI) 38.62 26.19
Support Level $2.66 $0.58
Resistance Level $3.09 $0.74
Average True Range (ATR) 0.16 0.10
MACD 0.00 -0.00
Stochastic Oscillator 31.25 10.38

Price Performance

Historical Comparison
ANIX
GNTA

About ANIX Anixa Biosciences Inc.

Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.

About GNTA Genenta Science S.p.A.

Genenta Science SPA is an industrial consolidator focused on acquiring majority or full ownership of privately held, established companies operating in Italian national-security-regulated sectors. Its acquisition activities span aerospace, defense, national security (including cybersecurity), and biotechnology/biosecurity, with a focus on businesses covered by Italy's Golden Power legislation.

Share on Social Networks: